(-0.35%) 5 053.00 points
(-0.47%) 38 323 points
(-0.16%) 15 672 points
(-0.84%) $82.66
(-5.85%) $1.706
(-0.03%) $2 341.40
(-0.23%) $27.30
(-1.04%) $913.20
(0.21%) $0.936
(0.92%) $11.00
(0.21%) $0.805
(-0.93%) $92.32
Live Chart Being Loaded With Signals
Basilea Pharmaceutica AG, a commercial stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives...
Stats | |
---|---|
Today's Volume | 17 064.00 |
Average Volume | 36 707.00 |
Market Cap | 489.13M |
EPS | CHF0 ( 2024-02-13 ) |
Last Dividend | CHF0 ( N/A ) |
Next Dividend | CHF0 ( N/A ) |
P/E | 47.38 |
ATR14 | CHF0.0560 (0.14%) |
Volume Correlation
Basilea Pharmaceutica AG Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Basilea Pharmaceutica AG Correlation - Currency/Commodity
Basilea Pharmaceutica AG Financials
Annual | 2023 |
Revenue: | CHF157.63M |
Gross Profit: | CHF130.84M (83.00 %) |
EPS: | CHF0.870 |
Q4 | 2023 |
Revenue: | CHF72.73M |
Gross Profit: | CHF55.93M (76.90 %) |
EPS: | CHF-1.780 |
Q2 | 2023 |
Revenue: | CHF84.91M |
Gross Profit: | CHF74.91M (88.23 %) |
EPS: | CHF2.66 |
Q4 | 2022 |
Revenue: | CHF89.12M |
Gross Profit: | CHF79.43M (89.13 %) |
EPS: | CHF2.04 |
Financial Reports:
No articles found.
Basilea Pharmaceutica AG
Basilea Pharmaceutica AG, a commercial stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. It offers Cresemba, an intravenous and oral azole antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union, as well as in Phase III clinical trials for invasive fungal infections in Japan. The company also provides Zevtera, an antibiotic for the treatment of community and hospital-acquired pneumonia, as well as in Phase III clinical trials for the treatment of acute bacterial skin and skin structure infections, and Staphylococcus aureus bacteremia. In addition, it engages in developing Derazantinib, a small molecule inhibitor, which is in phase 2 clinical trial for bile duct cancer, as well as in phase ½ clinical trial for bladder and stomach cancer; and Lisavanbulin, a tumor checkpoint controller drug. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Basel, Switzerland.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators